Medtronic PLC MDT
We take great care to ensure that the data presented and summarized in this overview for Medtronic plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MDT
View all-
Vanguard Group Inc Valley Forge, PA126MShares$10.9 Billion0.22% of portfolio
-
Black Rock Inc. New York, NY114MShares$9.79 Billion0.23% of portfolio
-
State Street Corp Boston, MA60.1MShares$5.16 Billion0.24% of portfolio
-
Jpmorgan Chase & CO New York, NY31.6MShares$2.72 Billion0.25% of portfolio
-
Capital Research Global Investors Los Angeles, CA30.9MShares$2.65 Billion0.63% of portfolio
-
Morgan Stanley New York, NY27MShares$2.32 Billion0.19% of portfolio
-
Geode Capital Management, LLC Boston, MA26.6MShares$2.29 Billion0.22% of portfolio
-
Massachusetts Financial Services CO Boston, MA25.5MShares$2.19 Billion0.69% of portfolio
-
Wellington Management Group LLP Boston, MA23.4MShares$2.01 Billion0.37% of portfolio
-
Bank Of America Corp Charlotte, NC23.1MShares$1.98 Billion0.19% of portfolio
Latest Institutional Activity in MDT
Top Purchases
Top Sells
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Insider Transactions at MDT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 01
2024
|
Randall J Hogan Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.42%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Kevin E Lofton Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-2.99%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Elizabeth G Nabel Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-1.21%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Denise M Oleary Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.25%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Kendall J Powell Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.42%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Craig Arnold Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.5%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Scott C Donnelly Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-0.97%
|
$15,360
$80.89 P/Share
|
May 01
2024
|
Lidia Fonseca Director |
SELL
Payment of exercise price or tax liability
|
Direct |
162
-4.21%
|
$12,960
$80.89 P/Share
|
May 01
2024
|
Andrea Jo Goldsmith Director |
SELL
Payment of exercise price or tax liability
|
Direct |
192
-2.26%
|
$15,360
$80.89 P/Share
|
Apr 29
2024
|
Gregory P Lewis Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,821
+50.0%
|
$145,680
$80.86 P/Share
|
Apr 29
2024
|
Kevin E Lofton Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+25.21%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Elizabeth G Nabel Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+12.01%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Denise M Oleary Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+2.73%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Kendall J Powell Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+4.49%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Craig Arnold Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+5.33%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Scott C Donnelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+9.86%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Lidia Fonseca Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+36.03%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Andrea Jo Goldsmith Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+20.3%
|
$173,200
$80.86 P/Share
|
Apr 29
2024
|
Randall J Hogan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,165
+4.56%
|
$173,200
$80.86 P/Share
|
Apr 08
2024
|
Michael Marinaro EVP & President, Surgical OU |
SELL
Open market or private sale
|
Direct |
854
-2.97%
|
$70,882
$83.14 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 204K shares |
---|---|
Exercise of conversion of derivative security | 36.2K shares |
Payment of exercise price or tax liability | 54.4K shares |
---|---|
Open market or private sale | 56.4K shares |